Covidien and Australian firm in novel tracer pact
This article was originally published in Clinica
Covidien has teamed up with Australian firm NewSouth Innovations to develop a novel tracer that can image dying cells after cancer treatment. The radiolabelled agent could be useful for monitoring treatment in patients with a number of solid tumour cancers. It may also prove valuable in the development of new cancer therapies.
You may also be interested in...
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.
The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.